Tilray Brands (2HQ.DE XETRA) down 5.05% before 08 Jan 2026 earnings: what to watch
2HQ.DE stock fell 5.05% intraday to €0.68 as Tilray Brands, Inc. prepares to report earnings on 08 Jan 2026 bmo. The drop followed heavy trading, with 122,839 shares changing hands versus an average of 16,595, signalling elevated investor attention. Investors will watch revenue beats or misses and the company’s commentary on U.S. regulatory changes. This earnings spotlight reviews recent results, valuation, trading signals, Meyka AI grading, and potential price targets for Tilray Brands (2HQ.DE) on XETRA in Germany.
Earnings setup for 2HQ.DE stock
Tilray Brands (2HQ.DE) reports before market open on 08 Jan 2026. Analysts expected weaker top-line figures heading into the release. The most recent quarter (2025-10-09) showed EPS -0.00259 versus estimate -0.02277, a small beat, while revenue was €178,953,659 versus estimate €205,751,000, a clear miss.
The trend shows improving EPS comparisons but recurring revenue shortfalls. Markets will parse management comments on margins, U.S. market access, and the company’s beverage and distribution segments for guidance.
Financials and valuation for 2HQ.DE stock
Tilray Brands shows mixed fundamentals. Market cap is €78,880,000 and shares outstanding are 116,000,000. Trailing twelve months metrics include EPS TTM -20.79 and P/E -0.03, reflecting wide losses on a per-share basis.
Valuation multiples are low on current price: P/S 0.11 and P/B 0.05, while the current ratio is 2.62 and debt to equity is 0.15. These figures point to balance-sheet liquidity but weak profitability and large historical impairments.
Trading action and technicals for 2HQ.DE stock
Intraday action shows a day low €0.66 and day high €0.71, with a relative volume 7.40 as retail flows and news drive moves. The stock opened at €0.70 and closed near €0.68 earlier.
Technical indicators are mixed. RSI reads 85.59 (overbought), MACD histogram is positive, and short-term momentum is strong. However, the 50-day average is €10.49 and the 200-day average is €7.29, illustrating the recent large retracement from 2024–2025 highs and extreme volatility.
Meyka AI rates 2HQ.DE with a score out of 100 and outlook for 2HQ.DE stock
Meyka AI rates 2HQ.DE with a score out of 100: 64.05 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a monthly target of €7.42 and a quarterly model value of €1.43. At the current price €0.68, the model implies a theoretical upside of 990.59% to the monthly figure and 110.29% to the quarterly figure. Forecasts are model-based projections and not guarantees. For more on our data, see the Meyka stock page: https://meyka.ai/stocks/2HQ.DE
Analyst and sector context for 2HQ.DE stock
Tilray operates in the Healthcare sector and the Drug Manufacturers – Specialty & Generic industry. The Healthcare sector shows a 1Y performance -4.67% and YTD -3.25%, reflecting mixed investor appetite for regulated growth stories.
Recent headlines tie Tilray’s moves to U.S. regulatory shifts and beverage expansion. Investors should note press activity, including company product announcements and coverage from industry outlets such as StockAnalysis and the company site Tilray press.
Risks and catalysts for 2HQ.DE stock
Key catalysts this quarter include the earnings release, commentary on U.S. regulatory access, and results from the beverage and distribution segments. Positive surprises on margins or new market access would be meaningful catalysts.
Primary risks include low liquidity at current prices, continued revenue misses, weak profitability metrics (negative ROE and ROIC), and sector volatility driven by policy shifts. Market-cap size €78.88M increases sensitivity to single large trades.
Final Thoughts
Tilray Brands (2HQ.DE) enters the 08 Jan 2026 bmo earnings report with mixed signals. Recent quarters show small EPS beats but recurring revenue misses, and the stock trades at €0.68 with elevated volume 122,839 versus an average 16,595. Valuation looks cheap on sales and book multiples, but profitability remains negative: EPS TTM -20.79 and P/E -0.03. Meyka AI’s forecast model projects a monthly figure of €7.42, implying large theoretical upside versus the current price, while a nearer-term quarterly projection is €1.43. These model projections are not guarantees and reflect scenarios where regulatory or operational catalysts materialise.
Our price-target framework: conservative €0.90, base €3.50, and bull €7.42. The base case assumes gradual revenue recovery and margin stabilization; conservative assumes continued revenue pressure. Traders should watch revenue guidance, gross margin trends, and management commentary on U.S. access. Meyka AI provides this analysis as an AI-powered market analysis platform; our Meyka grade and forecasts are informational and not investment advice.
FAQs
What should I expect from the 2HQ.DE earnings release on 08 Jan 2026?
Expect commentary on revenue drivers and U.S. regulatory impact. Prior quarter showed EPS beat -0.00259 and revenue shortfall €178,953,659 versus estimates. Watch guidance and margin updates closely.
How is 2HQ.DE stock valued versus peers?
2HQ.DE trades at P/S 0.11 and P/B 0.05, below many peers. Profitability is negative with EPS TTM -20.79, so low multiples reflect weak earnings and past impairments.
What are the main risks for 2HQ.DE stock after earnings?
Key risks are continued revenue misses, low liquidity at €78.88M market cap, and sector policy shifts. A weak outlook or lowered guidance could push volatility higher.
Does Meyka AI provide a forecast for 2HQ.DE stock?
Yes. Meyka AI’s forecast model projects monthly €7.42 and quarterly €1.43. These are model-based projections and not guarantees. Compare them to current price €0.68.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
